Tema Heart & Health ETF Rating $29.26 +0.15 (+0.52%) As of 07/25/2025 03:55 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Heart & Health ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HRTS Aggregate RatingModerate Buy 2.76Holdings in HRTS have an aggregate rating of Moderate Buy based on 642 analyst ratings issued in the past year covering 39 companies (83.4% of the portfolio).HRTS Aggregate Price Target$29.26High Prediction$29.26Average Prediction$29.26Low Prediction$29.26Holdings in HRTS have an aggregate price target of $29.26 and a range of $29.26 to $29.26 covering 39 companies (83.4% of the portfolio).HRTS Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy11 Buy rating(s)Moderate Buy24 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Heart & Health ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 39 HRTS Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings9.76%LLYEli Lilly and Company$811.73+0.8%4.9051 of 5 stars2.75$1,012.56 24.7%20Trending News4.54%ABTAbbott Laboratories$126.53+0.7%4.9902 of 5 stars2.87$144.47 14.2%234.17%RHHBYRoche$40.99-1.1%N/A2.577Trending News3.84%BBIOBridgeBio Pharma$46.30+1.4%4.6248 of 5 stars3.00$61.50 32.8%163.65%UNHUnitedHealth Group$280.69+0.8%4.9985 of 5 stars2.58$392.29 39.8%24Trending NewsUpcoming EarningsAnalyst Forecast3.49%BSXBoston Scientific$106.07-0.1%4.6338 of 5 stars3.04$117.50 10.8%26Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision3.24%VRTXVertex Pharmaceuticals$469.65-0.6%4.3205 of 5 stars2.52$512.30 9.1%27Positive NewsAnalyst Revision3.16%GILDGilead Sciences$116.20+2.7%4.8433 of 5 stars2.81$112.36 -3.3%26Trending NewsAnalyst Upgrade3.02%MDTMedtronic$92.91+0.6%4.652 of 5 stars2.59$98.19 5.7%22Positive News2.68%TMOThermo Fisher Scientific$478.61+0.8%4.9518 of 5 stars2.75$593.00 23.9%20Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision2.60%AMGNAmgen$306.58-0.6%4.3951 of 5 stars2.35$307.27 0.2%23Positive NewsAnalyst Forecast2.59%CRNXCrinetics Pharmaceuticals$30.99+1.9%3.6692 of 5 stars2.80$69.50 124.3%10Positive News2.53%MRKMerck & Co., Inc.$84.82+0.8%4.997 of 5 stars2.43$108.69 28.1%21Positive NewsUpcoming EarningsDividend Announcement2.26%ABBVAbbVie$190.22-0.3%4.8456 of 5 stars2.81$211.29 11.1%27Trending NewsUpcoming EarningsAnalyst Revision2.17%EWEdwards Lifesciences$79.92+5.4%4.3545 of 5 stars2.52$85.00 6.4%25Trending NewsEarnings ReportAnalyst ForecastGap UpHigh Trading Volume2.14%ALNYAlnylam Pharmaceuticals$328.81+0.2%4.0506 of 5 stars2.81$347.75 5.8%26News CoverageUpcoming Earnings2.12%PODDInsulet$290.22+1.3%4.6564 of 5 stars2.83$321.00 10.6%18Positive News2.08%BMYBristol Myers Squibb$48.44-1.0%4.658 of 5 stars2.33$58.53 20.8%21Trending NewsUpcoming Earnings2.08%REGNRegeneron Pharmaceuticals$563.10-0.3%4.8259 of 5 stars2.75$828.86 47.2%24Trending NewsUpcoming EarningsAnalyst Forecast2.05%DHRDanaher$205.60+1.4%4.8312 of 5 stars2.85$247.61 20.4%20Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision1.91%MCKMcKesson$711.80+0.2%4.6098 of 5 stars2.86$710.17 -0.2%14Positive News1.69%IONSIonis Pharmaceuticals$42.24+0.2%4.5283 of 5 stars2.62$55.67 31.8%13Upcoming Earnings1.61%CYTKCytokinetics$37.18-0.3%4.2253 of 5 stars2.93$70.92 90.8%15News Coverage1.49%DXCMDexCom$88.99+2.6%4.7227 of 5 stars2.90$98.72 10.9%20Upcoming Earnings1.38%ASNDAscendis Pharma A/S$167.47-0.5%3.6186 of 5 stars3.00$223.07 33.2%15Positive NewsAnalyst Revision1.32%MASIMasimo$164.62+2.0%3.9806 of 5 stars2.83$191.60 16.4%6Positive News1.17%ARWRArrowhead Pharmaceuticals$15.74-3.2%3.7811 of 5 stars2.75$43.71 177.7%8News CoveragePositive News1.07%VKTXViking Therapeutics$34.42+2.7%4.8502 of 5 stars3.00$86.92 152.5%14Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision1.06%MDGLMadrigal Pharmaceuticals$298.40-0.3%4.2728 of 5 stars2.89$420.63 41.0%9Insider Trade1.04%AKROAkero Therapeutics$50.56+0.1%3.7871 of 5 stars3.00$82.50 63.2%6Positive News0.95%MIRMMirum Pharmaceuticals$51.83-0.7%3.8562 of 5 stars3.13$65.50 26.4%80.92%INSMInsmed$103.95+0.4%3.9553 of 5 stars3.00$109.20 5.1%17News CoveragePositive NewsAnalyst ForecastInsider Trade0.91%GPCRStructure Therapeutics$17.94-1.8%2.9394 of 5 stars3.00$76.17 324.6%7Positive News0.85%WSTWest Pharmaceutical Services$263.32-5.7%4.4674 of 5 stars2.89$320.71 21.8%9Trending NewsEarnings ReportDividend IncreaseAnalyst Forecast0.72%SRRKScholar Rock$38.95-0.4%3.2487 of 5 stars3.13$42.67 9.5%80.35%MREOMereo BioPharma Group$1.76+1.1%1.7835 of 5 stars3.20$7.20 309.1%50.34%NTLAIntellia Therapeutics$13.60+6.4%4.5162 of 5 stars2.65$33.37 145.4%20News CoverageInsider Trade0.31%MTSRMetsera$40.47+2.1%N/A3.00$55.00 35.9%5Lockup ExpirationGap Down0.18%RCKTRocket Pharmaceuticals$3.14-2.2%4.8463 of 5 stars2.35$17.87 469.0%17Trending NewsAnalyst ForecastGap Down This page (NASDAQ:HRTS) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Heart & Health ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Heart & Health ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.